Provided by Tiger Trade Technology Pte. Ltd.

Forte BioSciences Inc

29.81
+2.228.05%
Post-market: 29.810.00000.00%19:45 EST
Volume:231.47K
Turnover:6.79M
Market Cap:373.43M
PE:-6.79
High:30.46
Open:27.25
Low:26.50
Close:27.59
52wk High:35.62
52wk Low:4.90
Shares:12.53M
Float Shares:9.26M
Volume Ratio:0.78
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3909
EPS(LYR):-12.1671
ROE:-110.72%
ROA:-58.07%
PB:4.44
PE(LYR):-2.45

Loading ...

Forte Biosciences präsentiert auf Investorenkonferenzen in New York, Boston und Miami

Reuters
·
8 hours ago

Forte Biosciences CEO to Present at Guggenheim Biotech Summit

Reuters
·
8 hours ago

Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses

Simply Wall St.
·
Jan 03

Forte Biosciences CFO Antony A. Riley Acquires Common Shares

Reuters
·
Jan 03

Forte Biosciences Grants 75,000 Stock Options to New Employee as Inducement Award

Reuters
·
Dec 23, 2025

Forte Biosciences Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Nov 25, 2025

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

THOMSON REUTERS
·
Nov 25, 2025

Forte Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 17, 2025

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)

TIPRANKS
·
Nov 15, 2025

Forte Biosciences posts Q3 net loss of $17.7 million

Reuters
·
Nov 14, 2025

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

THOMSON REUTERS
·
Nov 14, 2025

Forte Biosciences Q3 Basic EPS USD -0.99

THOMSON REUTERS
·
Nov 14, 2025

Forte Biosciences to Present at Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 04, 2025

BRIEF-Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules

Reuters
·
Oct 04, 2025

Forte Biosciences Announces Equity Inducement Awards for New Employees Under 2020 Incentive Plan

Reuters
·
Oct 04, 2025

Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium

Reuters
·
Sep 15, 2025

Forte Biosciences Initiated at Buy by Guggenheim

Dow Jones
·
Aug 18, 2025

Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target

MT Newswires Live
·
Aug 18, 2025

Forte Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 15, 2025

Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate

Benzinga
·
Aug 15, 2025